Edwards Lifesciences' New Transcatheter Heart Valve Data Demonstrate Positive Results

WASHINGTON, DC--(Marketwire - October 13, 2008) - Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced that new data from two studies of the Edwards SAPIEN transcatheter aortic heart valve with the RetroFlex transfemoral delivery system were presented today at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.